Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Non-Current Debt (2023 - 2025)

Goldenwell Biotech filings provide 3 years of Non-Current Debt readings, the most recent being $95588.0 for Q1 2025.

  • On a quarterly basis, Non-Current Debt changed N/A to $95588.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $95588.0, a N/A change, with the full-year FY2024 number at $95588.0, up 26.46% from a year prior.
  • Non-Current Debt hit $95588.0 in Q1 2025 for Goldenwell Biotech, roughly flat from $95588.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $95588.0 in Q4 2024 to a low of $75588.0 in Q4 2023.
  • Median Non-Current Debt over the past 3 years was $95588.0 (2024), compared with a mean of $88921.3.
  • The widest YoY moves for Non-Current Debt: up 26.46% in 2024, down 26.46% in 2024.
  • Goldenwell Biotech's Non-Current Debt stood at $75588.0 in 2023, then increased by 26.46% to $95588.0 in 2024, then changed by 0.0% to $95588.0 in 2025.
  • The last three reported values for Non-Current Debt were $95588.0 (Q1 2025), $95588.0 (Q4 2024), and $75588.0 (Q4 2023) per Business Quant data.